The Challenge Non-Typhoidal Salmonella (CHANTS) Consortium: Development of a non-typhoidal Salmonella controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK [version 2; peer review: 2 approved]
Invasive non-typhoidal Salmonella disease (iNTS) is a major cause of morbidity and mortality globally, particularly as a cause of bloodstream infection in children and immunocompromised adults in sub-Saharan Africa. Vaccines to prevent non-typhoidal Salmonella (NTS) would represent a valuable public...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wellcome
2023-09-01
|
| Series: | Wellcome Open Research |
| Subjects: | |
| Online Access: | https://wellcomeopenresearch.org/articles/8-111/v2 |
| _version_ | 1797663922861375488 |
|---|---|
| author | James E. Meiring Emma Smith Peter W.S. Hill Malick M. Gibani Megan E. Carey Christopher Chiu Melita Gordon Graham Cooke Thomas C. Darton Jay Hinton Christopher Smith Robert K.M. Choy Blanca Perez Sepulveda |
| author_facet | James E. Meiring Emma Smith Peter W.S. Hill Malick M. Gibani Megan E. Carey Christopher Chiu Melita Gordon Graham Cooke Thomas C. Darton Jay Hinton Christopher Smith Robert K.M. Choy Blanca Perez Sepulveda |
| author_sort | James E. Meiring |
| collection | DOAJ |
| description | Invasive non-typhoidal Salmonella disease (iNTS) is a major cause of morbidity and mortality globally, particularly as a cause of bloodstream infection in children and immunocompromised adults in sub-Saharan Africa. Vaccines to prevent non-typhoidal Salmonella (NTS) would represent a valuable public health tool in this setting to avert cases and prevent expansion of antimicrobial resistance. Several NTS and combination typhoidal-NTS vaccine candidates are in early-stage development, although the pathway to licensure is unclear due to challenges in conducting large phase III field trials. Controlled human infection models (CHIM) present an opportunity to accelerate vaccine development for a range of enteric pathogens. Several recent typhoidal Salmonella CHIMs have been conducted safely and have played pivotal roles in progressing vaccine candidates to pre-qualification and licensure. The Challenge Non-Typhoidal Salmonella (CHANTS) consortium has been formed with funding from the Wellcome Trust, to deliver the first NTS CHIM, which can act as a platform for future vaccine evaluation. This paper reports the conclusions of a consultation group workshop convened with key stakeholders. The aims of this meeting were to: (1) define the rationale for an NTS CHIM (2) map the NTS vaccine pipeline (3) refine study design and (4) establish potential future use cases. |
| first_indexed | 2024-03-11T19:21:48Z |
| format | Article |
| id | doaj.art-1feb40961b6541d49ab39f6dd848833b |
| institution | Directory Open Access Journal |
| issn | 2398-502X |
| language | English |
| last_indexed | 2024-03-11T19:21:48Z |
| publishDate | 2023-09-01 |
| publisher | Wellcome |
| record_format | Article |
| series | Wellcome Open Research |
| spelling | doaj.art-1feb40961b6541d49ab39f6dd848833b2023-10-07T01:00:00ZengWellcomeWellcome Open Research2398-502X2023-09-01822186The Challenge Non-Typhoidal Salmonella (CHANTS) Consortium: Development of a non-typhoidal Salmonella controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK [version 2; peer review: 2 approved]James E. Meiring0Emma Smith1Peter W.S. Hill2Malick M. Gibani3Megan E. Carey4https://orcid.org/0000-0002-7797-9080Christopher Chiu5Melita Gordon6https://orcid.org/0000-0002-0629-0884Graham Cooke7https://orcid.org/0000-0001-6475-5056Thomas C. Darton8https://orcid.org/0000-0003-2209-9956Jay Hinton9Christopher Smith10https://orcid.org/0000-0001-7369-2034Robert K.M. Choy11Blanca Perez Sepulveda12https://orcid.org/0000-0002-2891-4010Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, S10 2TN, UKDepartment of Infectious Disease, Imperial College London, London, W2 1PG, UKDepartment of Infectious Disease, Imperial College London, London, W2 1PG, UKDepartment of Infectious Disease, Imperial College London, London, W2 1PG, UKDepartment of Medicine, University of Cambridge, Cambridge, UKDepartment of Infectious Disease, Imperial College London, London, W2 1PG, UKInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, L69 3BX, UKDepartment of Infectious Disease, Imperial College London, London, W2 1PG, UKDepartment of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, S10 2TN, UKInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, L69 3BX, UKDepartment of Infectious Disease, Imperial College London, London, W2 1PG, UKPATH, Seattle, Washington, 98121, USAInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, L69 3BX, UKInvasive non-typhoidal Salmonella disease (iNTS) is a major cause of morbidity and mortality globally, particularly as a cause of bloodstream infection in children and immunocompromised adults in sub-Saharan Africa. Vaccines to prevent non-typhoidal Salmonella (NTS) would represent a valuable public health tool in this setting to avert cases and prevent expansion of antimicrobial resistance. Several NTS and combination typhoidal-NTS vaccine candidates are in early-stage development, although the pathway to licensure is unclear due to challenges in conducting large phase III field trials. Controlled human infection models (CHIM) present an opportunity to accelerate vaccine development for a range of enteric pathogens. Several recent typhoidal Salmonella CHIMs have been conducted safely and have played pivotal roles in progressing vaccine candidates to pre-qualification and licensure. The Challenge Non-Typhoidal Salmonella (CHANTS) consortium has been formed with funding from the Wellcome Trust, to deliver the first NTS CHIM, which can act as a platform for future vaccine evaluation. This paper reports the conclusions of a consultation group workshop convened with key stakeholders. The aims of this meeting were to: (1) define the rationale for an NTS CHIM (2) map the NTS vaccine pipeline (3) refine study design and (4) establish potential future use cases.https://wellcomeopenresearch.org/articles/8-111/v2Salmonella; Salmonella Typhimurium; Non-Typhoidal Salmonella; Human Challenge Model; Controlled Human Infection Model; Vaccineseng |
| spellingShingle | James E. Meiring Emma Smith Peter W.S. Hill Malick M. Gibani Megan E. Carey Christopher Chiu Melita Gordon Graham Cooke Thomas C. Darton Jay Hinton Christopher Smith Robert K.M. Choy Blanca Perez Sepulveda The Challenge Non-Typhoidal Salmonella (CHANTS) Consortium: Development of a non-typhoidal Salmonella controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK [version 2; peer review: 2 approved] Wellcome Open Research Salmonella; Salmonella Typhimurium; Non-Typhoidal Salmonella; Human Challenge Model; Controlled Human Infection Model; Vaccines eng |
| title | The Challenge Non-Typhoidal Salmonella (CHANTS) Consortium: Development of a non-typhoidal Salmonella controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK [version 2; peer review: 2 approved] |
| title_full | The Challenge Non-Typhoidal Salmonella (CHANTS) Consortium: Development of a non-typhoidal Salmonella controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK [version 2; peer review: 2 approved] |
| title_fullStr | The Challenge Non-Typhoidal Salmonella (CHANTS) Consortium: Development of a non-typhoidal Salmonella controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK [version 2; peer review: 2 approved] |
| title_full_unstemmed | The Challenge Non-Typhoidal Salmonella (CHANTS) Consortium: Development of a non-typhoidal Salmonella controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK [version 2; peer review: 2 approved] |
| title_short | The Challenge Non-Typhoidal Salmonella (CHANTS) Consortium: Development of a non-typhoidal Salmonella controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK [version 2; peer review: 2 approved] |
| title_sort | challenge non typhoidal salmonella chants consortium development of a non typhoidal salmonella controlled human infection model report from a consultation group workshop 05 july 2022 london uk version 2 peer review 2 approved |
| topic | Salmonella; Salmonella Typhimurium; Non-Typhoidal Salmonella; Human Challenge Model; Controlled Human Infection Model; Vaccines eng |
| url | https://wellcomeopenresearch.org/articles/8-111/v2 |
| work_keys_str_mv | AT jamesemeiring thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT emmasmith thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT peterwshill thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT malickmgibani thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT meganecarey thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT christopherchiu thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT melitagordon thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT grahamcooke thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT thomascdarton thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT jayhinton thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT christophersmith thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT robertkmchoy thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT blancaperezsepulveda thechallengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT jamesemeiring challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT emmasmith challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT peterwshill challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT malickmgibani challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT meganecarey challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT christopherchiu challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT melitagordon challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT grahamcooke challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT thomascdarton challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT jayhinton challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT christophersmith challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT robertkmchoy challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved AT blancaperezsepulveda challengenontyphoidalsalmonellachantsconsortiumdevelopmentofanontyphoidalsalmonellacontrolledhumaninfectionmodelreportfromaconsultationgroupworkshop05july2022londonukversion2peerreview2approved |